Having trouble accessing articles? Reset your cache.

Management tracks: Maze, Tiaki, NED, Annexon and more

Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe Inc.

Read the full 366 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE